{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:26:08Z","timestamp":1788297968567,"version":"build-2803163510"},"reference-count":53,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001554","name":"Massey University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Mental Health Nurs"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long\u2010acting opioids are prescribed as part of treatment for opioid use disorders; methadone and buprenorphine are well researched and commonly prescribed for the treatment of opioid use disorder. Meta\u2010analysis suggests that buprenorphine has a slightly poorer retention rate in treatment as compared to methadone. Benefits of buprenorphine\/naloxone include greater ease in ceasing treatment and less use of illicit opioids while in treatment as compared to methadone. There are a number of qualitative and mixed\u2010method studies that ask patients about their experiences of methadone maintenance and buprenorphine maintenance treatment. This research aimed to understand perspectives of receiving buprenorphine\/naloxone for the treatment of opioid use disorder. A qualitative descriptive approach was used. Seven participants with a current diagnosis of opioid use disorder treated with buprenorphine\/naloxone were interviewed. Thematic analysis extracted four themes: drivers for opioid substitution treatment change; readiness for buprenorphine\/naloxone substitution treatment; absence of effect from buprenorphine\/naloxone; and an increased sense of citizenship on buprenorphine\/naloxone. This study identified a number of factors influencing participants\u2019 decision\u2010making in transferring between methadone and buprenorphine\/naloxone for the treatment of their opioid use disorder. Methadone was preferred by those seeking sedation and wishing to continue using other opioids, and buprenorphine\/naloxone was most effective for participants no longer wishing to experience sedation and seeing opioid abstinence as an end point in their recovery. Changing treatment expectations are important to consider when determining medication selection and highlight the importance of quality information when determining the most suitable medication for the treatment of opioid use disorder.<\/jats:p>","DOI":"10.1111\/inm.12523","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:25:55Z","timestamp":1531959955000},"page":"226-236","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Readiness and recovery: Transferring between methadone and buprenorphine\/naloxone for the treatment of opioid use disorder"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-9888","authenticated-orcid":false,"given":"Blair","family":"Bishop","sequence":"first","affiliation":[{"name":"Massey University Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gilmour","sequence":"additional","affiliation":[{"name":"Massey University Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryle","family":"Deering","sequence":"additional","affiliation":[{"name":"Otago University Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.004"},{"issue":"3","key":"e_1_2_9_4_1","article-title":"A review of potential adverse effects of long\u2010term opioid therapy: A practitioner's guide","volume":"14","author":"Baldini A.","year":"2012","journal-title":"Primary Care Companion CNS Disorders"},{"key":"e_1_2_9_5_1","volume-title":"Recovery Writing Volume one: 2009\u20132010","author":"Bamber S.","year":"2010"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.9656834.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep06189"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02627.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0929"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.12.001"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2559"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e31829727b2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.05.032"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0349.2011.00795.x"},{"key":"e_1_2_9_16_1","first-page":"57","article-title":"Opioid substitution treatment in New Zealand: A 40\u2010year perspective","volume":"127","author":"Deering D.","year":"2014","journal-title":"New Zealand Medical Journal"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archinte.1967.00300010021004","article-title":"Heroin addiction \u2013 A metabolic disease","volume":"120","author":"Dole V.","year":"1967","journal-title":"New York Archives of Internal Medicine"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.13.13"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2007.04569.x"},{"issue":"3","key":"e_1_2_9_20_1","first-page":"CD002208","article-title":"Methadone maintenance at different dosages for opioid dependence","author":"Faggiano F.","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.02.008"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12926"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732311432718"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/14659891.2014.894589"},{"key":"e_1_2_9_25_1","unstructured":"Johnston L. D. O'malley P. M. Bachman J. G.&Schulenberg J. E.(2010).Monitoring the Future national survey results on drug use 1975\u20102009. Volume I: Secondary school students."},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial","volume":"164","author":"Kakko J.","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12796"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-6-200903170-00103"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.1996.tb01628.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230801935706"},{"key":"e_1_2_9_31_1","first-page":"123","volume-title":"The Effectiveness of Other Opioid Replacement Therapies: LAAM, Heroin, Buprenorphine, Naltrexone and Injectable Maintenance. Methadone Maintenance and Other Opioid Replacement Therapies","author":"Mattick R. P.","year":"1998"},{"issue":"2","key":"e_1_2_9_32_1","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick R.","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_9_33_1","volume-title":"The New Zealand Guidelines for Opioid Substitution Treatment","author":"Ministry of Health","year":"2014"},{"key":"e_1_2_9_34_1","unstructured":"National Institute on Drug Abuse (NIDA)(2002).National Drug Treatment Clinical Trials Network."},{"key":"e_1_2_9_35_1","unstructured":"NICE Technology Appraisal Guidance 114(2007).Methadone and buprenorphine for the management of opioid dependence. [Cited 12 09 2017]. Available from:www.nice.org.uk\/TA114"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.07.009"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-11-13"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490802268835"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.13.4.527"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2011.600381"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.694603"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00144-7"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.outlook.2005.03.005"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2004.03207.x"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2013.67.48-50"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050757"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.05.007"},{"key":"e_1_2_9_49_1","first-page":"22","article-title":"Recovery capital: A primer for addiction professionals","volume":"9","author":"White W.","year":"2008","journal-title":"Counselor"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2010.08.001"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.12.031"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.3.4.432"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2349-6"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00003-6"}],"container-title":["International Journal of Mental Health Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Finm.12523","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/inm.12523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T06:54:35Z","timestamp":1694501675000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/inm.12523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/inm.12523"],"URL":"https:\/\/doi.org\/10.1111\/inm.12523","archive":["Portico"],"relation":{},"ISSN":["1445-8330","1447-0349"],"issn-type":[{"value":"1445-8330","type":"print"},{"value":"1447-0349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]},"assertion":[{"value":"2018-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}